An engineered T cell, comprising: (i) one or more chimeric antigen receptors (CARs) comprising a plurality of binding moieties, wherein the plurality of binding moieties comprises: a first antigen binding domain capable of binding to an immune cell antigen; and a second antigen binding domain capable of binding to a disease-associated antigen, wherein the disease-associated antigen and the immune cell antigen are different, wherein each CAR of the one or more CARs further comprises a transmembrane domain and an intracellular signaling domain; and (ii) an enhancer moiety capable of enhancing one or more activities of the engineered T cell, wherein the enhancer moiety comprises a cytokine and/or a receptor thereof, wherein the cytokine is selected from IL-7 or IL-15; wherein an endogenous T cell receptor of the engineered T cell is inactivated, and wherein the engineered T cell exhibits: enhanced degree of persistence by remaining viable in vitro for at least about 20 days while in presence of cells that are heterologous to the engineered T cell; enhanced degree of expansion by at least about 10-fold within 15 days; and/or enhanced cytotoxicity against a target cell comprising the disease-associated antigen, as compared to that of a control T cell that comprises the one or more CARs and does not comprise the enhancer moiety. (i) one or more chimeric antigen receptors (CARs) comprising a plurality of binding moieties, wherein the plurality of binding moieties comprises: a first antigen binding domain capable of binding to an immune cell antigen; and a second antigen binding domain capable of binding to a disease-associated antigen, wherein the disease-associated antigen and the immune cell antigen are different, wherein each CAR of the one or more CARs further comprises a transmembrane domain and an intracellular signaling domain; and a first antigen binding domain capable of binding to an immune cell antigen; and a second antigen binding domain capable of binding to a disease-associated antigen, wherein the disease-associated antigen and the immune cell antigen are different, wherein each CAR of the one or more CARs further comprises a transmembrane domain and an intracellular signaling domain; and (ii) an enhancer moiety capable of enhancing one or more activities of the engineered T cell, wherein the enhancer moiety comprises a cytokine and/or a receptor thereof, wherein the cytokine is selected from IL-7 or IL-15; wherein an endogenous T cell receptor of the engineered T cell is inactivated, and wherein the engineered T cell exhibits: enhanced degree of persistence by remaining viable in vitro for at least about 20 days while in presence of cells that are heterologous to the engineered T cell; enhanced degree of expansion by at least about 10-fold within 15 days; and/or enhanced cytotoxicity against a target cell comprising the disease-associated antigen, as compared to that of a control T cell that comprises the one or more CARs and does not comprise the enhancer moiety. enhanced degree of persistence by remaining viable in vitro for at least about 20 days while in presence of cells that are heterologous to the engineered T cell; enhanced degree of expansion by at least about 10-fold within 15 days; and/or enhanced cytotoxicity against a target cell comprising the disease-associated antigen, as compared to that of a control T cell that comprises the one or more CARs and does not comprise the enhancer moiety.